Post written by Adi Hoess, CEO Recently, Ray Jupp, CSO and I went to ASGCT’s 2026 annual meeting in Boston, which showcased a range of viral and non-viral delivery platforms. Excellent progress has been made with non-viral delivery and the…
Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell‑specific targeting through nanobody conjugation CD8 nanobody conjugated tPNVs are simple to manufacture and display high stability at 4°C CD8-tPNVs precisely target CD8-expressing immune cells in vitro…
ViaNautis Bio has recently been featured in multiple articles in Drug Discovery World. Cell and gene therapies – looking forward Our Chief Business Officer, Sam Barker, is featured in Drug Discovery World, discussing the promise and challenges of cell and…
Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types.
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as Chief Scientific Officer (“CSO”), effective immediately. As CSO, Dr Jupp will be responsible for overseeing…
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder and CEO Dr Francesca Crawford who…
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler as independent Chairman to its Board of Directors. Dr Altschuler is a renowned biotech company…
– ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need – Series A led by 4BIO Capital, BGF, and UCB Ventures with participation…
SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed late seed funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut® platform technology (the…
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells. Commercialise novel cell delivery platform technology Develop novel delivery methods for research applications Revolutionise utility of live cell imaging to explore disease…